Oncology Drugs Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market as it emerges from the Covid 19 shut down.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology drugs market, and compares it with other markets.
2) By Drug Type: Chemotherapy; Harmone Therapy; Targeted Therapy; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
3) By Distribution Channel: Hospital Pharmacies; Online Stores; Others
4) By Route Of Administration: Oral; Parenteral; Others
5) By Drug Classification: Branded Drugs; Generic Drugs
Companies Mentioned: F.Hoffmann-La Roche Ltd.; Novartis AG; Gilead Sciences Inc.; Bayer AG; Takeda Pharmaceticals
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, oncology drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 3-5 business days.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oncology Drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oncology drugs indicators comparison.
Scope
Markets Covered:
1) By Type: Pharmaceutical Drugs; Biologics2) By Drug Type: Chemotherapy; Harmone Therapy; Targeted Therapy; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
3) By Distribution Channel: Hospital Pharmacies; Online Stores; Others
4) By Route Of Administration: Oral; Parenteral; Others
5) By Drug Classification: Branded Drugs; Generic Drugs
Companies Mentioned: F.Hoffmann-La Roche Ltd.; Novartis AG; Gilead Sciences Inc.; Bayer AG; Takeda Pharmaceticals
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, oncology drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Report Structure7. Oncology Drugs Market Trends And Strategies8. Impact Of COVID-19 On Oncology Drugs21. Key Mergers And Acquisitions In The Oncology Drugs Market25. Copyright And Disclaimer
3. Oncology Drugs Market Characteristics
4. Oncology Drugs Market Product Analysis
5. Oncology Drugs Market Supply Chain
6. Oncology Drugs Market Customer Information
9. Oncology Drugs Market Size And Growth
10. Oncology Drugs Market Regional Analysis
11. Oncology Drugs Market Segmentation
12. Oncology Drugs Market Metrics
13. Asia-Pacific Oncology Drugs Market
14. Western Europe Oncology Drugs Market
15. Eastern Europe Oncology Drugs Market
16. North America Oncology Drugs Market
17. South America Oncology Drugs Market
18. Middle East Oncology Drugs Market
19. Africa Oncology Drugs Market
20. Oncology Drugs Market Competitive Landscape
22. Market Background: Pharmaceutical Drugs Market
23. Recommendations
24. Appendix
Executive Summary
Major companies in the oncology drugs market include F.Hoffmann-La Roche Ltd., Novartis AG, Gilead Sciences Inc., Bayer AG and Takeda Pharmaceuticals.The global oncology drugs market is expected to grow from $199.95 billion in 2021 to $223.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $328.22 billion in 2026 at a CAGR of 10.1%.
The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, brain tumor, and other different cancer types. The oncology drugs market is segmented into lung cancer, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, kidney cancer, brain tumor, thyroid cancer, skin cancer, bladder cancer, cervical cancer, blood cancer, and others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma).
The main types of chemotherapy, hormone therapy, targeted therapy, lung cancer, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, kidney cancer, brain tumor, thyroid cancer, skin cancer, bladder cancer, cervical cancer, blood cancer, others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma). Breast cancer drugs are used to target and destroy breast cancer cells. The different types include pharmaceutical drugs, and biologics. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The drugs are distributed by hospital pharmacies, retail pharmacies/ drug stores and others.
North America was the largest region in the oncology drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The outbreak of Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of 'lock down' and the outbreak had a negative impact on businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one has been relatively unaffected however due to continued availability of drugs during government lock downs and inelasticity of demand. It is expected that the oncology market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy.
Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs.
Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs.
The countries covered in the oncology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.
Companies Mentioned
- F.Hoffmann-La Roche Ltd.
- Novartis AG
- Gilead Sciences Inc.
- Bayer AG
- Takeda Pharmaceticals
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 300 |
Published | March 2022 |
Forecast Period | 2022 - 2026 |
Estimated Market Value ( USD | $ 223.21 billion |
Forecasted Market Value ( USD | $ 328.22 billion |
Compound Annual Growth Rate | 10.1% |
Regions Covered | Global |
No. of Companies Mentioned | 5 |